

SpeeDx, SynGenis partner for custom oligonucleotide synthesis

28 September 2021 | News

The partnership will bolster the internal capacity of SpeeDx to support large-scale increases in manufacturing



SpeeDx, a developer of innovative molecular diagnostic solutions announced an investment in SynGenis, an experienced oligonucleotide manufacturer based in Western Australia. The partnership will bolster the internal capacity of SpeeDx to support large-scale increases in manufacturing while developing and expanding the sovereign capacity of important raw materials used in molecular diagnostics.

"We have invested considerable resources into our production scale-up processes to support the increase in testing seen as a result of the global pandemic," said Tom Lin, SpeeDx Director, Global Operations. "Enhancing our access to quality raw materials ensures we remain committed to maintaining supply chain security for our customers worldwide."

"As Australia's experienced commercial oligonucleotide manufacturer with significant expertise, we are delighted to have this strategic partnership to supply custom oligonucleotides with the highest quality and fast turnaround time," said Rakesh Veedu, Founder and MD, SynGenis.

Steve Arnott, Chairman, SynGenis said, "The partnership with SpeeDx is a strong vote of confidence in the capability and capacity of Syngenis staff and operations and provides a significant platform for our future development."

In addition to securing the local supply chain, SpeeDx investment in the local industry serves to fast track the growth and expand the reach of SynGenis in the global diagnostic market.